NRG-GU011

Open to Accrual

Return to Protocol Table

A Phase II Double-Blinded, Placebo Controlled Trial of Prostate Oligometastatic Radiotherapy with or without Androgen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean)

Principal Investigator

Bridget Koontz, MD,

Status

Open to Accrual

Date Opened To Accrual

December 08 2021

Disease Site

Genitourinary [GU]

Prostate

Phase

Developmental Therapeutics

Yes

Primary Objective

Compare conventional radiological progression-freesurvival (rPFS) for positron emission tomography (PET)-detected, biochemicallyrecurrent, oligometastatic, castration-sensitive prostate cancer patients treatedwith SABR plus placebo vs. SABR plus relugolix.

Patient Population

Pathologically proven diagnosis of prostate adenocarcinoma and are recurrent oligometastatic.

Target Accrual

260

Protocol Documents

Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.

Other

NRG-GU011 The Promethean Study Overview by Bridget Koontz, MD

Patient Study Webpage

To learn more about this study, visit the Patient Study Webpage.

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.